KR890010191A - 만손주혈흡충에 대한 백신 - Google Patents

만손주혈흡충에 대한 백신 Download PDF

Info

Publication number
KR890010191A
KR890010191A KR1019880016089A KR880016089A KR890010191A KR 890010191 A KR890010191 A KR 890010191A KR 1019880016089 A KR1019880016089 A KR 1019880016089A KR 880016089 A KR880016089 A KR 880016089A KR 890010191 A KR890010191 A KR 890010191A
Authority
KR
South Korea
Prior art keywords
monoclonal antibody
manson
insects
blood
vaccines against
Prior art date
Application number
KR1019880016089A
Other languages
English (en)
Inventor
에이취. 킹 찰스
리처드 올즈 지.
난두리 쟈아스리
에이. 에프. 마흐모드 아델
알. 레트 로날드
Original Assignee
원본미기재
클리브랜드 대학병원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 클리브랜드 대학병원 filed Critical 원본미기재
Publication of KR890010191A publication Critical patent/KR890010191A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

만손주혈흡충에 대한 백신
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 세포로스 비드상에 고정된 본 발명에 따르는 항-주혈흡충 쥐과의 단일클론성 항체(31-3B6 항체)에 대한 가용성 성충((adult worm)항원 (“SWAP”)의 면역친화성 크로마토 그래피에 의해 수행된 본 발명에 따르는 항원(31-3B6)의 정제를 나타낸다. 제1도는 회수된 유분에 대해 수행된 SDS-폴리아크릴아미드겔 전기영동의 결과를 도시한다. 겔의 은 염색후에, 비-결합기생물질을 함유하는 레인 1은 다중 단백질 밴드를 나타낸다. 특이적으로 결합된 물질을 함유하고 있는 레인 2는 68,000 분자량에서의 단일 밴드를 나타낸다. 분자량 표준의 상대적인 이동은 제1도의 좌측 가장자리에 표시되어 있다.

Claims (5)

  1. 만손 주혈흡충의 68,000 분자량 항원과 결합하는 단일 클론성 항체.
  2. 제1항에 있어서, 쥐과의 하이브리도마에 의해 분비되는 것을 특징으로 하는 단일클론성 항체.
  3. 제1항에 있어서, 상기 항체가 하이브리도마 세라인 ATCC HB 9597과 동일한 특성을 가지는 하이브리도마 셀라인에 의해 생성되는 것을 특징으로 하는 단일클론성 항체.
  4. 만손 주혈흡충 감염에 대한 면역감작을 위한 백신으로서, 제1항의 단일클론성 항체에 의하여 인지되는 실질적으로 순수한 항원의 유효량과 생리적으로 허용가능한 희석제를 포함하는 것을 특징으로 하는 백신.
  5. 하이브리도마 셀라인 ATCC HB 9597.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880016089A 1987-12-03 1988-12-03 만손주혈흡충에 대한 백신 KR890010191A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12855687A 1987-12-03 1987-12-03
US128,556 1987-12-03

Publications (1)

Publication Number Publication Date
KR890010191A true KR890010191A (ko) 1989-08-07

Family

ID=22435898

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880016089A KR890010191A (ko) 1987-12-03 1988-12-03 만손주혈흡충에 대한 백신

Country Status (3)

Country Link
EP (1) EP0318879A1 (ko)
KR (1) KR890010191A (ko)
AU (1) AU2648388A (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100783A0 (en) * 1992-01-28 1992-09-06 Yeda Res & Dev Vaccine against schistosomiasis
US8734807B1 (en) 2013-04-06 2014-05-27 Gabriel Langlois-Rahme Preventing and curing Schistosomiasis mansoni by inhibiting Trk receptors on female Schistosoma

Also Published As

Publication number Publication date
AU2648388A (en) 1989-06-08
EP0318879A1 (en) 1989-06-07

Similar Documents

Publication Publication Date Title
ATE208820T1 (de) Humanisierte antikoerper
PT865448E (pt) Apoptose induzida pelo anticorpo monoclonal anti-her2
KR900013986A (ko) 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
DK0853633T3 (da) Humant monoklonalt antistof imod hepatitis B virus overfladeantigen (HBVsAg)
ATE132197T1 (de) Monoklonale antikörper
DK388384D0 (da) Monoklone antistoffer med specifitet for membran-associerede antigene, deres fremstilling og anvendelse
DE3785038D1 (de) Monoklonale antikoerper gegen nicht reduzierte, nicht enzymatisch glykolysierte proteine.
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
DK0476226T3 (da) Monoklonalt antistof mod humant IgE
ES2070820T3 (es) Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
ES2127531T3 (es) Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
KR890010191A (ko) 만손주혈흡충에 대한 백신
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
KR890008313A (ko) 안티 pci모노클론 항체
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
Fernandez et al. Immunochemical studies of a murine polyreactive IgG2b autoantibody with rheumatoid factor activity
AU1493995A (en) Monoclonal antibody
KR950704478A (ko) 비(b)형 간염 표면 항원에 대해 활성적인 인체 단일클론 항체의 제조방법(production of human monoclonal antibodies active against hepatitis b surface antigen)
Cohen Structure of antibodies
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid